Latest Stem Cells News

Page 3 of 3
NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.
Ada Torres
Ada Torres
23 July 2025
NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.
Ada Torres
Ada Torres
27 June 2025
Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.
Ada Torres
Ada Torres
20 June 2025
CLINUVEL’s Phase II pilot study reveals afamelanotide monotherapy does not trigger repigmentation in vitiligo patients, underscoring the necessity of adjunct NB-UVB phototherapy.
Victor Sage
Victor Sage
18 June 2025
Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.
Ada Torres
Ada Torres
16 May 2025
Chimeric Therapeutics reports encouraging interim results from its ADVENT-AML Phase 1B trial, with two of three newly diagnosed AML patients achieving remission using their novel CORE-NK cell therapy combined with standard treatment.
Ada Torres
Ada Torres
15 May 2025
Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.
Ada Torres
Ada Torres
15 May 2025
A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.
Ada Torres
Ada Torres
5 Feb 2025
Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.
Ada Torres
Ada Torres
31 Jan 2025